

ASX Announcement

16 June 2009

Cytopia secures key patents

Cytopia Ltd (ASX: CYT) announced today that it has secured key patents protecting its two clinical drug assets CYT997 and CYT387, with a new patent grant in Australia and a new patent allowance in the United States of America.

CYT997, an anti-cancer vascular disrupting agent currently in Phase II clinical trials, is being developed under the protection of a broad set of patent applications. Cytopia has now secured the grant of the Australian patent, which covers a novel class of compounds including CYT997.

Patent number 2004294354 was sealed on the 4th of June 2009, and covers new chemical entities as well as methods of use of tubulin inhibitors. The patent has a twenty year term expiring on 3 December 2024, with a possible extension of up to 5 years under Pharmaceutical Extension of Term provisions.

Corresponding patent applications are under examination in Europe, India, China, Israel and New Zealand, are awaiting examination in the US, Japan, Mexico, South Korea, Canada and Brazil, and a patent has been granted in South Africa.

Cytopia is also continuing to expand its patent monopoly over the JAK2 enzyme target. United States patent application 11/248478 entitled "Method of selecting or designing a compound which interacts with JAK2" has recently been allowed by the United States Patent and Trademark Office. This patent utilises the JAK2 crystal structure first solved by Cytopia and Monash University and published in Lucet et al, Blood, 1 January 2006, Vol. 107, No. 1, pp. 176-183.

Cytopia is also the exclusive licensee of several granted patents for the validated drug targets JAK1 and JAK2, and has developed a library of new chemical entities which inhibit JAK2. The most advanced compound is CYT387, a novel oral JAK2 inhibitor, and expected to enter Phase I clinical trials for myelofibrosis in the second half of 2009.

"The granting of these important patents further protects the company's valuable clinical drug assets", said Mr Andrew Macdonald, CEO. "Our growing intellectual property estate is very important for the commercialisation of our various drug candidates."

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the development of new drugs to treat cancer and other diseases. Cytopia conducts its drug development through subsidiaries based in Australia and USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, currently being trialed in Phase II clinical studies. This compound is delivered orally as well as intravenously. Cytopia also has built on its range of JAK and other kinase inhibitors with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009.

Enquiries:

Mr Andrew Macdonald

Chief Executive Officer

T: +61 3 9208 4232

andrew.macdonald@cytopia.com.au

Website: www.cytopia.com.au